Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service

Arq Bras Endocrinol Metabol. 2011 Dec;55(9):686-91. doi: 10.1590/s0004-27302011000900003.


Objective: To analyze the costs related to visits and drug prescription in outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service.

Subjects and methods: A prospective and experimental study was carried out. Seventy one patients were divided into two groups: control and pharmaceutical care. Patients in the pharmaceutical care group were followed up monthly by a single clinical pharmacist.

Results: The pharmaceutical care group had a statistically significant reduction in costs of metformin and emergency department visits, and increased costs with their family physicians. On the other hand, the control group had a statistically significant increase of 21.3% in the general costs of treatment and visits.

Conclusion: The pharmaceutical care group maintained the same costs related to drugs and visits, while the control group showed a significant increase in general costs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / economics
  • Family Practice / economics
  • Female
  • Glyburide / economics
  • Glyburide / therapeutic use
  • Health Care Costs / statistics & numerical data*
  • Humans
  • Hypoglycemic Agents / economics*
  • Hypoglycemic Agents / therapeutic use
  • Insulin / economics
  • Insulin / therapeutic use
  • Male
  • Medication Therapy Management / economics*
  • Metformin / economics
  • Metformin / therapeutic use
  • Middle Aged
  • Prospective Studies


  • Hypoglycemic Agents
  • Insulin
  • Metformin
  • Glyburide